IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents

Molecular Cancer Therapeutics

Volumn 7, Issue 8, 2008, Pages 2426-2434

  Liberatore, Anne Marie ^a   Coulomb, Hélène ^a   Pons, Dominique ^a   Dutruel, Olivier ^a   Kasprzyk, Philip G ^b   Carlson, Mark ^b   Nelson, Ann Savola ^b   Newman, Simon P ^c   Stengel, Chloe ^c   Auvray, Pierrïck ^d   Hesry, Vincent ^d   Foll, Béatrice ^d   Narboux, Nadine ^d   Morlais, Delphine ^d   Le Moing, Mélissa ^d   Bernetiere, Sonia ^a   Dellile, Raphael ^a   Camara, Jose ^a   Ferrandis, Eric ^a   Bigg, Dennis C ^a   Prévost, Grégoire P ^a   more..

^a Institut Henri Beaufour   (France)

^b Biomeasure Inc   (United States)

^c ST MARY S HOSPITAL   (United Kingdom)

^d C RIS Pharma ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; BETA TUBULIN; C 3915; COLCHICINE; DOXORUBICIN; E 2656; EPOTHILONE B; IMIDAZOLE DERIVATIVE; IRC 083827; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N [2 FLUORO 4 [4 [2 (PHENOXYMETHYL) 1H IMIDAZOL 4 YL]PHENOXY]PHENYL]SULFAMIDE; NAVELBINE; PACLITAXEL; T 7402; TUBULIN; UNCLASSIFIED DRUG; V 2264; VINCA ALKALOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG IDENTIFICATION; ENDOTHELIUM CELL; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CELL CYCLE; CELL DIVISION; DRUG RESISTANCE, NEOPLASM; HUMANS; IMIDAZOLES; MICE; NEOVASCULARIZATION, PATHOLOGIC; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS; TUBULIN;

EID: 53349127748     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0208     Document Type: Article

References (50)

1. Iwasaki S, Shirai R. Natural organic compounds that affect to microtubule functions: syntheses and structure-activity relationships of combretastatins, curacin A and their analogs as the colchicine-site ligands on tubulin. Yakugaku Zasshi 2000;120:875-89.
2. Hamel E. Natural products which interact with tubulin in the Vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 1992;55:31-51.
3. Hamel E. Antimitotic natural products and their interactions with tubulin. Med Res Rev 1996;16:207-31.
4. Dorr RT, Dvorakova K, Snead K, Alberts DS, Salmon SE, Pettit GR. Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. Invest New Drugs 1996;14:131-7.
5. Lin CM, Singh SB, Chu PS, et al. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 1988;34:200-8.
6. Kruczynski A, Hill BT. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol 2001;40:159-73.
7. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 1991;51:2212-22.
8. Rose WC. Taxol: a review of its preclinical in vivo antitumor activity. Anticancer Drugs 1992;3:311-21.
9. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 1998;9:1-17.
10. Choy H. Taxanes in combined modality therapy for solid tumors. Crit Rev Oncol Hematol 2001;37:237-47.
11. Ark-Otte J, Samelis G, Rubio G, Lopez Saez JB, Pinedo HM, Giaccone G. Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep 1998;5:249-55.
12. Shionoya M, Jimbo T, Kitagawa M, Soga T, Tohgo A. DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci 2003;94:459-66.
13. Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 1996;56:1091-7.
14. Yang CP, Verdier-Pinard P, Wang F, et al. A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence. Mol Cancer Ther 2005;4:987-95.
15. Gokmen-Polar Y, Escuin D, Walls CD, et al. β-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Cancer Res 2005;65:9406-14.
16. Berrieman HK, Lind MJ, Cawkwell L. Do β-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 2004;5:158-64.
17. Yin S, Cabral F, Veeraraghavan S. Amino acid substitutions at proline 220 of β-tubulin confer resistance to paclitaxel and colcemid. Mol Cancer Ther 2007;6:2798-806.
18. Wang L, Woods KW, Li Q, et al. Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J Med Chem 2002;45:1697-711.
19. Pan XD, Fang WS. Recent progress in structure-activity relationship studies on the anticancer drug colchicine and its analogues. Yao Xue Xue Bao 2002;37:821-7.
20. Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998;18:259-96.
21. Islam MN, Iskander MN. Microtubulin binding sites as target for developing anticancer agents. Mini Rev Med Chem 2004;4:1077-104.
22. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anti-Canc Agents 2005;5:65-71.
23. Beckers T, Reissmann T, Schmidt M, et al. 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors. Cancer Res 2002;62:3113-9.
24. Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 1997;57:3208-13.
25. Segreti JA, Polakowski JS, Koch KA, et al. Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother Pharmacol 2004;54:273-81.
26. Young SL, Chaplin DJ. Combretastatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs 2004;13:1171-82.
27. West CM, Price P. Combretastatin A4 phosphate. Anticancer Drugs 2004;15:179-87.
28. Kuppens IE, Witteveen PO, Schot M, et al. Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors. Invest New Drugs 2007;25:227-35.
29. Newman SP, Foster PA, Stengel C, et al. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. Clin Cancer Res 2008;14:597-606.
30. Shelanski ML, Gaskin F, Cantor CR. Microtubule assembly in the absence of added nucleotides. Proc Natl Acad Sci U S A 1973;70:765-8.
31. Lee JC, Timasheff SN. In vitro reconstitution of calf brain microtubules: effects of solution variables. Biochemistry 1977;16:1754-64.
32. Tahir SK, Kovar P, Rosenberg SH, Ng SC. Rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin. Biotechniques 2000;29:156-60.
33. Brezak MC, Quaranta M, Mondesert O, et al. A novel synthetic inhibitor of CDC25 phosphatases: BN82002. Cancer Res 2004;64:3320-5.
34. Newman SP, Leese MP, Purohit A, et al. Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. Int J Cancer 2004;109:533-40.
35. Prevost G, Lanson M, Thomas F, et al. Molecular heterogeneity of somatostatin analogue BIM-23014C receptors in human breast carcinoma cells using the chemical cross-linking assay. Cancer Res 1992;52:843-50.
36. Loganzo F, Discafani CM, Annable T, et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res 2003;63:1838-45.
37. Ferlini C, Distefano M, Pignatelli F, et al. Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors. Br J Cancer 2000;83:1762-8.
38. Giaccone G, Ark-Otte J, Rubio GJ, et al. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs. Int J Cancer 1996;66:760-7.
39. Attard G, Greystoke A, Kaye S, De Bono J. Update on tubulin-binding agents. Pathol Biol (Paris) 2006;54:72-84.
40. Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 2002;83:21-38.
41. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
42. Donovan D, Brown NJ, Bishop ET, Lewis CE. Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Angiogenesis 2001;4:113-21.
43. Seve P, Mackey J, Isaac S, et al. Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005;4:2001-7.
44. Maeno K, Ito K, Hama Y, et al. Mutation of the class I β-tubulin gene does not predict response to paclitaxel for breast cancer. Cancer Lett 2003;198:89-97.
45. Monzo M, Rosell R, Sanchez JJ, et al. Paclitaxel resistance in non-small-cell lung cancer associated with β-tubulin gene mutations. J Clin Oncol 1999;17:1786-93.
46. Aapro MS, Conte P, Esteban GE, Trillet-Lenoir V. Oral vinorelbine: role in the management of metastatic breast cancer. Drugs 2007;67:657-67.
47. Hande KR, Hagey A, Berlin J, et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 2006;12:2834-40.
48. Kuncl RW, Bilak MM, Craig SW, Adams R. Exocytotic " constipation" is a mechanism of tubulin/lysosomal interaction in colchicine myopathy. Exp Cell Res 2003;285:196-207.
49. McKeage MJ. The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. Expert Opin Investig Drugs 2008;17:23-9.
50. Koletsky AJ, Guerra ML, Kronish L. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer. Cancer J 2003;9:286-92.